1,143
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Balancing patient value and payer cost in hematologic malignancies: can it be done?

&
Pages 123-126 | Received 24 Oct 2017, Accepted 20 Feb 2018, Published online: 13 Mar 2018
 

Declaration of interest

CR Flowers discloses being a Consultant: Abbvie, Bayer, Celgene (unpaid), Genentech/Roche (unpaid), Gilead, OptumRx, Spectrum. Research Funding for this Work: Burroughs Wellcome Fund, National Cancer Institute. Other Research Funding: Abbvie, Celgene, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics, Eastem Cooperative Oncology Group, National Cancer Institute, V Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. A reviewer on this manuscript has disclosed they are a shareholder of Pharmerit, a HEOR consulting form, which receives funding from a large number of pharmaceutical companies.

Additional information

Funding

This paper was funded by the Burroughs Wellcome Fund, NCI K24CA208132.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.